@NotGenentech

DYODD.

 USA
Joined March 2023
  • Tweets3.3K
  • Following172
  • Followers813
22Media
profitons bien de la jeunesse retweeted
Nicholas Hornstein
@GIMedOncOct 24
NICHE-2. Keeping it short because the plot speaks for itself. 1. Rename it Chalabi's disease 2. Stop operating on patients first For those who don't know: 111 patients with locally advanced dMMR colon cancer got one dose of ipi and two of nivo, then surgery. Zero events. A flat line. Next up? Avoid the surgery altogether. #ESMO2026 @Onco_Nexus @OncoAlert @TheGutOncLab
9
41
4
139
13,986
profitons bien de la jeunesse retweeted
Nicholas Fabiano, MD
@NTFabianoOct 17
Delusional optimism is extremely underrated for mental health.
117
1,028
102
8,922
509,351
youtube.com/watch?v=OnRWlxI1…

ROSALÍA: Magnolias (Live) - SNL

Musical guest ROSALÍA performs “Magnolias” on Saturday Night Live...

youtube.com
348
All this talk about Daraxonrasib activity on G12D tumors yet nothing on the insane GLP/TOX package...$RVMD
1
9
2,845
B7H3 is dead. Long live SeZ6 and Dll3.
1
389
profitons bien de la jeunesse retweeted
Jacob Plieth@JacobPliethSep 25
Ah, just reminding myself of this amazing moment in biotech $NKTR $LLY
Jacob Plieth@JacobPlieth7 Aug 2023
Now there's a PR headline you don't often see $NKTR $LLY
1
4
58
12,052
I take it back $ERAS.
718
profitons bien de la jeunesse retweeted
🧙🏻@augurbioSep 5
Are we ever going to get an IPO that isn’t atopic derm or is that just the only indication that exists now?
1
1
20
4,829
profitons bien de la jeunesse retweeted
Eric Topol
@EricTopolSep 4
The bottleneck for effective cancer treatment is not the science "It is no longer the science... that is holding back potential cures, but our capacity to try new medicines in clinical trials." by @RuxandraTeslo @nytopinion nytimes.com/2026/09/04/opini…

Opinion | This Is the Biggest Obstacle to New Cancer Cures (Gift Article)

It is too hard for medical researchers to start clinical trials.

nytimes.com
26
152
19
609
96,315
profitons bien de la jeunesse retweeted
Kevin A. Scott, PhD
@SculpturatusSep 4
ok but what does my sexual orientation have to do with submitting a paper to science
340
659
94
8,609
247,269
profitons bien de la jeunesse retweeted
pharmabro@pharmabro0782Aug 31
Replying to @DmitryKovalchuk
I made this sometime ago... and it remains true
5
2
39
19,568
profitons bien de la jeunesse retweeted
Matthias Schmidt
@eurofounderAug 29
Replying to @patrickc
Patrick delete this slandering post immediately or you will face the EU jail
59
20
3
4,838
214,693
profitons bien de la jeunesse retweeted
Rod Wong, MD
@docrodwongAug 28
a logical move to gain time ahead of competition
Kyle LaHucik@ky_lahucikAug 27
Lilly no longer discloses its Phase 1 pipeline, furthering the industry's shielding of drug R&D details as global competition heats up @endpts spoke w/analysts + former presidents of Lilly Research Labs about the move from the world's largest pharma endpoints.news/lillys-move-t…

Lilly's move to hide Phase 1 pipeline draws mixed reviews

Is it the right call for Eli Lilly to stop disclosing its Phase 1 pipeline? Analysts and former Lilly execs weigh in.

endpoints.news
2
1
23
9,241
Hot tumor is hot. More news at 10. $MRNA
1
10
1,365
profitons bien de la jeunesse retweeted
Eric Topol
@EricTopolAug 16
Replying to @DarioAmodei
I wish it was possible but it’s not. We are not going to “cure most human disease in ~5-10 years.”
5
5
1
83
7,062
profitons bien de la jeunesse retweeted
Brittany Trang@brittanytrangAug 14
Breaking: Three sources confirmed to @statnews that the FTC and a group of attorneys general are looking into EHR giant Epic's practices for potential antitrust action. Read more about the context, including the counts that the FTC is probing on: statnews.com/2026/08/14/epic…

Epic’s alleged anticompetitive practices under scrutiny from federal, state investigators

Epic Systems is the subject of a broad inquiry into its business practices, people who were contacted by FTC investigators told STAT.

statnews.com
1
10
1
18
3,401
$RVMD quarterly cash burn rate is impressive.
2
1,838
Someone give the Pfizer BD team a raise.
Tim Carmichael
@TimCarmichael3Aug 4
Pfizer axes ex-Metsera obesity asset and GIPR prospect $PFE fiercebiotech.com/biotech/pf…

Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout

Pfizer has axed two clinical-stage obesity programs, including a GLP-1 receptor agonist that came over in the $10 billion acquisition of Metsera. | Pfizer has axed two clinical-stage obesity progra...

fiercebiotech.com
3
1,311
profitons bien de la jeunesse retweeted
Alex Hirsch
@_AlexHirschJul 31
Replying to @sama
What if you just talked to your children
453
19,193
347
225,524
3,493,751
profitons bien de la jeunesse retweeted
Drew Armstrong
@ArmstrongDrewJul 30
🍿Okay -- we heard you, and we're giving the people what they want: @jrkelly will join me, @PeterKolchinsky + @Fiona_MIT on stage in Boston next week to debate US-China biotech. In-person only. Tickets link in the tweet below (and we expect to sell out).
Drew Armstrong
@ArmstrongDrewJul 28
🇨🇳💊The China Biotech Debate: Aug. 6 in Boston🧬🇺🇸 Next month we're launching an in-person series on: ➡️How China is changing the definition of innovation ➡️US investors vs US industrial policy ➡️Downstream impact of big pharma's China strategy events.endpoints.news/the-ch…

The China Biotech Debate: Boston

The China biotech story is evolving incredibly quickly, with new developments in Washington, fresh deals by US investors and pharma companies, and new companies and scientific advances seemingly...

events.endpoints.news
4
8
8
60
25,199
Load more